

Figure S1. Sensitivity analysis for conversion rate. (A) LEN combined with ICIs, (B) LEN alone, (C) LEN combined with ICIs and LRT, and (D) LEN combined with LRT. ICI, immune checkpoint inhibitor; LEN, lenvatinib; LRT, locoregional therapy.

